Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic diseases. The company advances a pipeline of product candidates designed to target the classical complement pathway, a key component of the immune system implicated in these debilitating conditions. Its lead programs address unmet needs in areas such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy associated with age-related macular degeneration. Annexon, Inc. emphasizes innovative monoclonal antibodies that modulate complement activity to halt disease progression and preserve neurological and retinal function. Operating within the biotechnology industry of the healthcare sector, the company conducts clinical trials to evaluate the safety, efficacy, and potential of its therapies in patient populations. Founded in 2011 and headquartered in Brisbane, California, Annexon, Inc. plays a role in advancing treatments for complement-mediated disorders through rigorous scientific research and development efforts.